Truist lowered the firm’s price target on Janux Therapeutics (JANX) to $80 from $100 and keeps a Buy rating on the shares. The firm is updating its model after Q4 earnings and recent prostate cancer developments, slightly lowering its max penetration for JANX007 due to new entrants while maintaining its probabilit of success assumptions, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating
- Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating
- Janux Therapeutics price target lowered to $100 from $150 at Cantor Fitzgerald
- Janux Therapeutics price target lowered to $68 from $72 at Guggenheim
- Janux Therapeutics: Rebuilding Confidence After JANX007 Setback with 2026 Clinical Catalysts and Validated PSMA x CD3 Platform